- Home
- UHG vs VNDA Comparison
UHG vs VNDA Comparison
Compare UHG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHG
- VNDA
- Stock Information
- Founded
- UHG 2004
- VNDA 2002
- Country
- UHG United States
- VNDA United States
- Employees
- UHG N/A
- VNDA N/A
- Industry
- UHG Homebuilding
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- UHG Consumer Discretionary
- VNDA Health Care
- Exchange
- UHG Nasdaq
- VNDA Nasdaq
- Market Cap
- UHG 281.1M
- VNDA 270.2M
- IPO Year
- UHG N/A
- VNDA 2006
- Fundamental
- Price
- UHG $6.12
- VNDA $5.17
- Analyst Decision
- UHG
- VNDA Strong Buy
- Analyst Count
- UHG 0
- VNDA 2
- Target Price
- UHG N/A
- VNDA $15.50
- AVG Volume (30 Days)
- UHG 20.9K
- VNDA 775.4K
- Earning Date
- UHG 11-08-2024
- VNDA 11-06-2024
- Dividend Yield
- UHG N/A
- VNDA N/A
- EPS Growth
- UHG 47.07
- VNDA N/A
- EPS
- UHG 2.33
- VNDA N/A
- Revenue
- UHG $414,814,052.00
- VNDA $190,858,000.00
- Revenue This Year
- UHG N/A
- VNDA $6.70
- Revenue Next Year
- UHG N/A
- VNDA $51.03
- P/E Ratio
- UHG $2.58
- VNDA N/A
- Revenue Growth
- UHG N/A
- VNDA N/A
- 52 Week Low
- UHG $5.09
- VNDA $3.30
- 52 Week High
- UHG $9.48
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- UHG 58.85
- VNDA 59.66
- Support Level
- UHG $5.39
- VNDA $4.56
- Resistance Level
- UHG $6.23
- VNDA $4.89
- Average True Range (ATR)
- UHG 0.37
- VNDA 0.18
- MACD
- UHG 0.05
- VNDA 0.04
- Stochastic Oscillator
- UHG 77.88
- VNDA 66.67
About UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.